8-K

0001193125-22-074718.txt : 20220314 0001193125-22-074718.hdr.sgml : 20220314 20220314170003 ACCESSION NUMBER: 0001193125-22-074718 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220314 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220314 DATE AS OF CHANGE: 20220314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Colfax CORP CENTRAL INDEX KEY: 0001420800 STANDARD INDUSTRIAL CLASSIFICATION: PUMPS & PUMPING EQUIPMENT [3561] IRS NUMBER: 541887631 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34045 FILM NUMBER: 22737374 BUSINESS ADDRESS: STREET 1: 2711 CENTERVILLE ROAD STREET 2: SUITE 400 CITY: WILMINGTON STATE: DE ZIP: 19808 BUSINESS PHONE: (302) 252-9160 MAIL ADDRESS: STREET 1: 2711 CENTERVILLE ROAD STREET 2: SUITE 400 CITY: WILMINGTON STATE: DE ZIP: 19808 8-K 1 d328429d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 14, 2022

Colfax Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-34045

54-1887631

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

2711 Centerville Road, Suite 400

Wilmington, DE 19808

(Address of principal executive offices) (Zip Code)

(302) 252-9160

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

CFX

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events.

On March 14, 2022, Colfax Corporation (the “Company” or “Colfax”) issued a press release announcing that its board of directors has authorized and declared the pro rata distribution (the “Distribution”) of 90% of the outstanding shares of common stock of ESAB Corporation (“ESAB”) to holders of record of the Company’s common stock as of the close of business on March 22, 2022 (the “Record Date”). The Distribution is expected to be payable after the market close on April 4, 2022. As a result of the Distribution, each holder of record of Colfax common stock will receive one share of ESAB common stock for every three shares of Colfax common stock held at the close of business on the Record Date. Following the Distribution, Colfax will retain 10% of the outstanding shares of ESAB common stock, which it intends to divest within 12 months after the separation in a tax-efficient exchange for its outstanding debt. The completion of the Distribution is subject to a number of customary conditions, including the Securities and Exchange Commission (“SEC”) having declared effective ESAB’s Registration Statement on Form 10, as amended.

The Company also announced that, following its stockholders’ approval on February 28, 2022 of three alternative amendments to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of Colfax common stock at a ratio determined by the Board, the Board has approved a one-for-three reverse stock split, and immediately following such split, a corresponding authorized share reduction. Such reverse stock split and corresponding authorized share reduction will be effected immediately following completion of the Distribution along with the Company’s name change to “Envois Corporation”. In connection with the reverse stock split, every three shares of Colfax common stock issued and outstanding as of the effective date will be automatically changed into one share of Enovis common stock. The Company’s stockholders will receive cash in lieu of any fractional shares they would otherwise be entitled to receive in the Distribution and reserve stock split.

A copy of the press release announcing these matters is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Cautionary Note Concerning Forward-Looking Statements

This Current Report on Form 8-K includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax’s plans, objectives, outlook, expectations and intentions, including the intended separation of ESAB (the “Separation”), and the timing, method and anticipated benefits of the Separation, and other statements that are not historical or current fact. Forward-looking statements are based on Colfax’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax’s results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including the rise, prevalence and severity of variants of the virus, actions by governments, businesses and individuals in response to the situation, such as the scope and duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response; the war in Ukraine and escalating geopolitical tensions as a result of Russia’s invasion of Ukraine; macroeconomic conditions; material delays and cancellations of medical procedures; supply chain disruptions; the impact on creditworthiness and financial viability of customers; risks relating to the Separation, the uncertainty of obtaining regulatory approvals, and a favorable tax opinion; Colfax’s ability to satisfactorily complete steps necessary for the Separation and related transactions to be generally tax-free for U.S. federal income tax purposes; the ability to satisfy the necessary conditions to complete the Separation on a timely basis, or at all; the timing of effectiveness of ESAB’s Form 10, as amended; the ability to realize the anticipated benefits of the Separation; developments related to the impact of the COVID-19 pandemic on the Separation, and the financial and operating performance of each company following the Separation; other impacts on Colfax’s business and ability to execute business continuity plans; and the other factors detailed in Colfax’s reports filed with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Colfax’s filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This Current Report on Form 8-K speaks only as of the date hereof. Colfax disclaims any duty to update the information herein.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy securities.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.


Exhibit No.		Description

99.1		Press release issued by Colfax Corporation, dated March 14, 2022

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 14, 2022


COLFAX CORPORATION

By:		/s/ Christopher M. Hix
Name:		Christopher M. Hix
Title:		Executive Vice President, Finance, Chief Financial Officer

EX-99.1 2 d328429dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

Colfax Announces Expected Completion Date of April 4, 2022 for Spin-Off of ESAB Corporation

•

“When-issued” trading of ESAB and Colfax ex-distribution common stock expected to begin on March 21, 2022

•

Record date for distribution of ESAB common stock will be March 22, 2022

•

Distribution Date expected to be April 4, 2022

WILMINGTON, DE, March 14, 2022 (GLOBE NEWSWIRE)—Colfax Corporation (“Colfax”) (NYSE: CFX) today announced that its Board of Directors has declared (a) a pro rata distribution of 90% of the outstanding common stock of ESAB Corporation (“ESAB”) to Colfax shareholders of record as of the close of business on March 22, 2022 (the “Record Date”), and (b) that the previously announced reverse stock split of all issued and outstanding shares of Colfax Common Stock will be effected at a one-for-three ratio (the “Reverse Stock Split”) following the distribution of the ESAB shares. The distribution is expected to be payable after the market close on April 4, 2022 (“Distribution Date”). As a result of the distribution, Colfax shareholders will receive one share of ESAB common stock for every three shares of Colfax common stock they hold on the Record Date (pre-Reverse Stock Split ratio). Immediately following the distribution, Colfax will retain 10% of the outstanding shares of ESAB common stock, which Colfax intends to divest within 12 months after the separation in a tax-efficient exchange for its outstanding debt.

Fractional shares of ESAB common stock will not be distributed to Colfax shareholders. Instead, the fractional shares of ESAB common stock will be aggregated and sold in the open market, with the net proceeds distributed pro rata in cash payments to the Colfax shareholders who otherwise would have received fractional shares of ESAB common stock.

No action is required by Colfax shareholders to receive the distributed shares of ESAB common stock. Colfax shareholders who hold Colfax common stock on the Record Date will either receive a book-entry account statement reflecting their ownership of ESAB common stock, or their brokerage account will be credited with ESAB shares. The shares are expected to be credited to “street name” shareholders through the Depository Trust Corporation (DTC) on the Distribution Date.

An Information Statement containing details regarding the distribution of ESAB common stock and ESAB’s business and management following the consummation of the distribution will be mailed to Colfax shareholders prior to the Distribution Date. The distribution of ESAB common stock remains subject to the satisfaction or waiver of customary conditions, including the Securities and Exchange Commission (“SEC”) having declared effective ESAB’s Registration Statement on Form 10, as amended, which ESAB has filed with the SEC and is available at the SEC’s website at http://www.sec.gov, as described in the Information Statement.

Colfax also announced that it expects “when-issued” trading of ESAB common stock to begin on March 21, 2022, on the New York Stock Exchange (“NYSE”), under the symbol “ESAB WI.” “Regular-way” trading of ESAB common stock is expected to begin on the NYSE on April 5, 2022, under the symbol “ESAB.” The “when-issued” trading market is a market for ESAB common stock that will be distributed to holders of Colfax common stock after the market close on April 4, 2022. Shareholders who own Colfax common stock at the close of business on the Record Date will be entitled to ESAB common stock distributed pursuant to the distribution and may trade this entitlement to shares of ESAB common stock, without Colfax common stock they own, on the “when-issued” market.

Upon completion of the distribution, Colfax will effect the Reverse Stock Split and change its name to Enovis Corporation (“Enovis”). Following the distribution, Enovis will trade on the NYSE under the symbol “ENOV.”

Shares of Colfax common stock will continue to trade “regular way” on the NYSE under the symbol “CFX” through the Distribution Date. Colfax expects that beginning March 21, 2022 there will be two markets in Colfax common stock on the NYSE: “regular-way” under the symbol “CFX” and “ex-distribution” under the symbol “ENOV WI.” Prior to the Distribution Date, shares of Colfax common stock that trade in the “regular-way” market will trade with the right to receive shares of ESAB common stock on the Distribution Date. Shares of Colfax common stock that trade in the “ex-distribution” market will trade without the right to receive shares of ESAB common stock on the Distribution Date.

Holders of Colfax common stock are encouraged to consult with their financial advisors regarding the specific implications of selling Colfax common stock on or before the Distribution Date.

For U.S. federal income tax purposes, Colfax U.S. shareholders (other than those subject to special rules) generally should not recognize gain or loss as a result of the distribution, except with respect to cash received in lieu of fractional shares of ESAB common stock. Colfax shareholders are urged to consult with their tax advisors with respect to the U.S. federal, state and local or foreign tax consequences, as applicable, of the distribution.

ABOUT COLFAX

Colfax is a leading diversified technology company that provides orthopedic and fabrication technology products and services to customers around the world, principally under the DJO and ESAB brands. The Company uses its Colfax Business System, a comprehensive set of tools and processes, to create superior value for customers, stockholders and associates. After the separation, Colfax, which will become Enovis, will focus on specialty medical technologies and ESAB will focus on fabrication technologies.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax’s plans, objectives, outlook, expectations and intentions, including the intended separation of Colfax’s

fabrication technology and specialty medical technology businesses (the “Separation”), and the timing, method and anticipated benefits of the Separation and other statements that are not historical or current fact. Forward-looking statements are based on Colfax’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax’s results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including the rise, prevalence and severity of variants of the virus, actions by governments, businesses and individuals in response to the situation, such as the scope and duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response; the war in Ukraine and escalating geopolitical tensions as a result of Russia’s invasion of Ukraine; macroeconomic conditions; material delays and cancellations of medical procedures; supply chain disruptions; the impact on creditworthiness and financial viability of customers; risks relating to the Separation, including the uncertainty of obtaining regulatory approvals, and a favorable tax opinion; Colfax’s ability to satisfactorily complete steps necessary for the Separation and related transactions to be generally tax-free for U.S. federal income tax purposes; the ability to satisfy the necessary conditions to complete the Separation on a timely basis, or at all; the ability to realize the anticipated benefits of the Separation, developments related to the impact of the COVID-19 pandemic on the Separation, and the financial and operating performance of each company following the Separation; other impacts on Colfax’s business and ability to execute business continuity plans; and the other factors detailed in Colfax’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Colfax’s filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. Colfax disclaims any duty to update the information herein.

NOT AN OFFER

This announcement is for informational purposes only and shall not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities.

Mike Macek

Vice President, Finance

Colfax Corporation

+1-302-252-9129

investorrelations@colfaxcorp.com

Source: Colfax Corporation

EX-101.SCH 3 cfx-20220314.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cfx-20220314_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cfx-20220314_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g328429g0314084117280.jpg GRAPHIC begin 644 g328429g0314084117280.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HK#U;6[O2+6:[FTS=;Q'[RSC)'TQ3/#?B>/Q&)S':O!Y) M.Y@LVD:0SG"SV\A<+]00#71QR++&LB,& M5AD$=Q2C4C)M+=%3HSA%2DM'LQU%%%69!1110 4444 %%%% !1137D6-"[LJ MJ.2S' % #J*S#XATD9_XF$! ZL&R!^/2KUO[ M(16FCK(H96# ]"*&FMQ*49;,Y_QQ_P BG>?0?SKG_AA_J]0^JUT'CC_D4[SZ M#^=<]\,V5(=19F"J"I))P!7EU?\ ?X>G^9[U#_D4U/\ $OT-SQSJTFEZ"P@8 MK-<-Y:L.H'>F> +=(O"\4@'S2NS,?6L3XCW=MJJVXCZXKKC2ITYNIU9Y\Z]:K2C1>T?(T:*JVFHV=^";2ZAFQUV." M1]:DFN[>VQY]Q%%NZ>8X7/YUMS*USF<6G9K4FHJI_:EA_P _UM_W^7_&I8[N MVFC:2*XA=$^\RN"!]:%)/J-QDMT3453_ +5T_'_'_:_]_E_QJVK*Z!T8,I&0 M0<@T)I["::W%HHHIB(;JXBM+66XG8+%$I=F/8"O.=-O9_''BG;=EAIEN#*+8 M'Y2 <#=ZDFNC^(,KQ>$IPIQYDB(WTS_]:L#X8*/M.I/W"(/U->9B*CGBH4.F M[\SVL'1C3P-7%?:V7EMK^)Z(L2)&(U150# 4# Q]*\D&K2:7X\N'T\>7"]UY M;PK]UQG!XKU^J7]D:=]N^V_8H/M77S?+&[\ZZ<3AY5>7D=K.YQX+%0H<_M(\ MW,K&#XV\1C1+%8HV83S X"'#8]CV^M>4VUUXDUB^\C1XE\T\E8XE.!ZLS9_, MFMSQW,USXJN5<_+$%11Z#&?ZUW'P]L(;7PTDZ*/-N'+.V.3@X KFI8N=;$RI M+1(]"K@:&&P4:\X\TI=^ESGM*A\5Z25'B'2H9+8\?:[-@6C_ -]!V]Q6^-6> MRN Z'*9^9<\$5UQ Q7"ZXB1ZM*D8 48.!VKVJ+O[LM3Y/'/D2J0T9K>,I5F\ M&W,J'*LJD'\:P?ADH>'458 J2H((X-7-69F^'4^[MP/IFJGPP_U>H?5:\:NK M9A%>3_4^GPDN;)YR[M?H,^)%K;V]M8F&"*++G.Q N>/:MKP596DWA:U>2U@= MSG+-&"3S67\3O^/6Q_WV_E6YX&_Y%.T_'^=332^OS]/\C2LW_95-_P!Y_J9/ MQ"OI=-TJWL[,?9XIV(_8A;E[X0> M2O),X&T?G69%XAMK@>5H]K-?;?E#1+LB7_@1P/RS71[-0KNI*6ZLD<7MG4PB MHQAL[M_YG'>.RVC^);34+$^3.\>YBG&X@]_6N^M?L^K:;;7,UO%()(PV'0-C M(]Z\T\?)>_VG!)?-'YCQ96.+)6,9Z9/4^]>C>&O^1:T__K@O\JPPLF\35CT. MO'02P-"?757/,O%.A/X:UM+FV0?9G?S(25R%/=3_ )Z5Z'H6K:;J&@&^2."" M-5/VE H 4@3/JES90IYHVV\)B'[N M/U(Q]X]?TKH%544*H"J!@ # %-B=)8U>-@R, 5(Z$4^O5A%16AX%2;D]0HHH MJR#(\3:6VK^'[JTCQYK+NCS_ 'AR*X7X;W/V;7;NSE!226+ 5N#N4\CZ]:]1 MK U7PI9ZC>I?P/)9WZ$,MQ#U)]QT-<6(P\I58UH;K\4>EA,9&-">&J?#+KV9 MOU3U&^6PMO-*&1V8)'&#@NQ. !51(]?1 C3Z?*1QYAC=2?P!Q4MOIC_:EN[Z MOTKO;FUAN[=H)XQ)&XP5->$YX@QL M)%8=E*/E9AA(_\ =7H/K7IT,6Y1]VFXOS/"KX!RE>I532Z(K^*8!;>!9H<8 MVHN1[YK(^&'^KU#ZK71ZSH^IZQ9SV;WMK';R'C$#;@/KNJAH7A74?#RS"TU" MV?S<9\R!N,?1JXJE.I+%QJVT2/MC_OM_*MOP M-_R*=I^/\ZK:[X7U+Q!%"EWJ%LGE$D>5 W/YM5O2=&U;1]/BLH+ZT>*/H7MV MR?\ QZB%.:Q3OU\SA_'EY-=^)A92NPMXMJJF>.>IKU& MQMXK6P@@@0)&B * /:N?\1^#8-?D6Y6@>&O\ D6M/_P"N"_RJCJGA"RU73TMY991,C%Q<<%BQZY]:DL-*UG3[&*SB MU.U>.)=J,]J=V.W1J*5&I3Q$ZC5U(,1B:57!TZ,79Q;_ .')]2N);RY_LJS< MJ[#-S*O_ "R0]A_M'MZ=:Y_QGX4BN-*2ZT^$+-:)@HH^_&/ZBM[2M+U#3G/F MWEO,CL7E80$.['OG=_2M&Z2[>,"TDAC?/)EC+ CZ BMZE%5J;51;G+1Q$L/5 MC*D]OQ]3A?A]XDR!HUT_(YMV)ZCNO^%>AUP$WPZG?4&O(=3CMY#)YBB* @(> MO'S5V=E'J$>1>W$$W "F.(H<^IR36>#5:$/9U5ML_(VS)X:I4]K0>^Z[,N44 M45VGFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 &444 ?__9 end XML 7 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 14, 2022
Cover [Abstract]
Entity Registrant Name	Colfax CORP
Amendment Flag	false
Entity Central Index Key	0001420800
Document Type	8-K
Document Period End Date	Mar. 14, 2022
Entity Incorporation State Country Code	DE
Entity File Number	001-34045
Entity Tax Identification Number	54-1887631
Entity Address, Address Line One	2711 Centerville Road
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19808
City Area Code	(302)
Local Phone Number	252-9160
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	CFX
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

XML 8 d328429d8k_htm.xml IDEA: XBRL DOCUMENT 0001420800 2022-03-14 2022-03-14 Colfax CORP false 0001420800 8-K 2022-03-14 DE 001-34045 54-1887631 2711 Centerville Road Suite 400 Wilmington DE 19808 (302) 252-9160 false false false false Common Stock, par value $0.001 per share CFX NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d328429d8k.htm cfx-20220314.xsd cfx-20220314_lab.xml cfx-20220314_pre.xml d328429dex991.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d328429d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d328429d8k.htm" ] }, "labelLink": { "local": [ "cfx-20220314_lab.xml" ] }, "presentationLink": { "local": [ "cfx-20220314_pre.xml" ] }, "schema": { "local": [ "cfx-20220314.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cfx", "nsuri": "http://www.colfaxcorp.com/20220314", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d328429d8k.htm", "contextRef": "duration_2022-03-14_to_2022-03-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d328429d8k.htm", "contextRef": "duration_2022-03-14_to_2022-03-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.colfaxcorp.com//20220314/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-074718-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-074718-xbrl.zip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end